RxSight/$RXST

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About RxSight

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Ticker

$RXST
Sector
Primary listing

Employees

498

RxSight Metrics

BasicAdvanced
$381M
-
-$0.80
1.15
-

What the Analysts think about RxSight

Analyst ratings (Buy, Hold, Sell) for RxSight stock.

Bulls say / Bears say

Preliminary Q1 2025 revenue was about $37.9 million, up 28% year-over-year, driven by a 36% rise in LAL procedures. (Nasdaq)
The installed base of Light Delivery Devices grew 34% year-over-year to 1,084 units as of June 30, 2025, demonstrating strong uptake of the LAL platform. (Nasdaq)
In Q2 2025, the company received FDA approval to broaden the Light Adjustable Lens dioptric power range to -2.0 to +3.0 diopters and introduce new LDD software updates, expanding its addressable patient base. (Nasdaq)
Total revenue for Q2 2025 decreased by 4% year-over-year to $33.6 million and dropped 11% compared to the previous quarter, indicating near-term headwinds for sales. (Nasdaq)
Sales of Light Delivery Devices fell sharply by 49% year-over-year in Q2 2025 to 40 units, pointing to reduced demand for its capital equipment products. (Nasdaq)
Management lowered its full-year 2025 revenue outlook from $160 – $175 million to $120 – $130 million after Q2 results, signaling reduced growth expectations. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 14 Sept 2025.

RxSight Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RxSight Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RXST

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs